Charles Schwab Investment Management Inc. lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

and MDM2 program to treat hematological malignancies and solid tumors. Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of ...

It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

For BMS, the data positions CC-486 into a segment of the AML market that for the time being sidesteps competition from Venclexta and other drugs coming through the pipeline like Roche’s MDM2 ...

Expert Rev Anticancer Ther. 2012;12(1):41-49. Uterine serous cancer (USC) is a highly aggressive variant of endometrial cancer. USC is resistant to cytotoxic chemotherapy and is responsible for ...